Boundless Bio, Inc.
BOLDBoundless Bio is a clinical-stage oncology company focused on developing a new class of cancer therapeutics called ecDNA-directed therapeutic candidates (ecDTx).
Table of contents
Earnings
Next report
Aug 4, 2026 (In 6 days)Competitors
By market cap
By revenue growth
Profile
Boundless Bio is a clinical-stage oncology company focused on developing a new class of cancer therapeutics called ecDNA-directed therapeutic candidates (ecDTx). The company utilizes its proprietary Spyglass platform to identify and target extrachromosomal DNA (ecDNA), which is a primary driver of oncogene amplification and treatment resistance in approximately 14% to 17% of cancer patients. Their mission is to deliver transformative, synthetic lethal therapies for patients with previously intractable oncogene-amplified tumors.
Boundless Bio is a pioneer in the ecDNA field, claiming to be the first company to bring an ecDNA-directed therapeutic candidate into clinical trials.
Questions, answered.
- What is Boundless Bio, Inc.'s market cap?
- Boundless Bio, Inc. (BOLD) has a market capitalization of $55.7M and trades on NASDAQ.
- Who are Boundless Bio, Inc.'s competitors?
- Boundless Bio, Inc.'s key competitors include Erasca, Eli Lilly, Black Diamond Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Boundless Bio, Inc. partner with?
- Boundless Bio, Inc.'s notable partners include ARCH Venture Partners, Roche, Amgen.
- Where is Boundless Bio, Inc. headquartered?
- Boundless Bio, Inc. is headquartered in United States of America and employs approximately 72 people. It has been publicly traded since 2024.